Abstract
A variety of skin diseases are associated with impaired barrier function. The crucial pillars in therapy of previously mentioned conditions are avoidance of triggers, skin protection and individually adapted medical therapy. Until recently, besides of topical corticosteroids, the treatment options were limited. However, a variety of new therapies of skin barrier-related skin diseases became available over the last years. Our goal was to investigate new findings and treatment options in skin diseases with barrier dysfunction, emphasizing on contact dermatitis, hand eczema and atopic dermatitis. Besides of new relatively nonspecific anti-inflammatory therapies, such as topical calcineurin inhibitors, crisaborole and delgocitinib, also highly specific targeted treatments are currently under investigation, and some already available on the market. Worth mentioning is dupilumab, the first biologic drug approved for treatment of atopic dermatitis, but used also off-label for treatment of hand eczema. There are ongoing trials investigating tralokinumab and lebrikizumab for atopic dermatitis therapy. Anti-IL-31 monoclonal antibodies were reported to improve atopic dermatitis-related pruritus. This review focuses on new findings and treatment options for skin diseases with barrier dysfunction regarding their efficacy, safety profile and mechanism of action.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have